

CLAIM AMENDMENTS

This listing of claims will replace all prior versions and listings of all claims in the application.

1. (Currently Amended) ~~A non-naturally-occurring-GPA-~~ A variant hG-CSF protein comprising at least two amino acid substitutions ~~as compared to hG-CSF protein, wherein said substitutions are at positions 17 and 28 as compared to the protein of SEQ ID NO:2, wherein said HG-CSF protein has increased thermal stability as compared to the protein of SEQ ID NO: 2.~~
2. (Currently Amended) ~~A non-naturally-occurring-GPA-~~ A variant hG-CSF protein according to claim 1 wherein said GPA hG-CSF protein has comprises at least one further substitution at a position selected from the group consisting of positions 14, 20, 21, 24, 27, 31, 32, 34, 35, 38, 78, 79, 82, 85, 89, 91, 92, 99, 102, 103, 106, 107, 109, 110, 113, 116, 117, 120, 145, 146, 147, 148, 151, 153, 155, 156, 157, 160, 161, 164, 167, 168 and 170.
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Currently Amended) ~~A non-naturally-occurring-GPA~~ A variant hG-CSF protein according to claim 1, wherein said GPA hG-CSF protein further comprises at least one of said further substitution at a position substitutions-selected from the group consisting of the positions 78, 85, 89, 92, 103, 110, 113, 151, 153, and 168.
9. (Currently Amended) ~~A non-naturally-occurring-GPA~~ A variant hG-CSF protein according to claim 8, wherein said substitutions are 17A₁ and 28A, and said further substitution is 110I (SEQ ID NO: 19).
10. (Currently Amended) ~~A non-naturally-occurring-GPA~~ A variant hG-CSF protein according to claim 8, wherein said substitutions are 17L₁ and 28A, and said further substitutions are 78F, 85F, 151I, 153I, and 168F (SEQ ID NO: 20).

11. (Currently Amended) ~~A non-naturally occurring GPA~~ A variant hG-CSF protein according to claim 8, wherein said substitutions are 17L~~[[,]]~~ and 28A, and said further substitutions are 78F, 85F, and 168F (SEQ ID NO: 21).
12. (Currently Amended) ~~A non-naturally occurring GPA~~ A variant hG-CSF protein according to claim 8, wherein said substitutions are 17A~~[[,]]~~ and 28A, and said further substitutions are 89F, 92F, 103V, and 110I (SEQ ID NO: 22).
13. (Currently Amended) ~~A non-naturally occurring GPA~~ A variant hG-CSF protein according to claim 8, wherein said substitutions are 17A~~[[,]]~~ and 28A, and said further substitutions are 89F, and 92F (SEQ ID NO: 23).
14. (Currently Amended) ~~A non-naturally occurring GPA~~ A variant hG-CSF protein according to claim 8, wherein said substitutions are 17A and 28A (SEQ ID NO: 24).
15. (Currently Amended) ~~A non-naturally occurring GPA~~ A variant hG-CSF protein according to claim 8, wherein said substitutions are 17L~~[[,]]~~ and 28A, and said further substitutions are 78F, 85F, 113L, 151I and 153I (SEQ ID NO: 25).
16. (Currently Amended) A recombinant nucleic acid encoding the non-naturally occurring GPA an hG-CSF protein of claim 1.
17. (Currently Amended) A pharmaceutical composition comprising ~~a GPA~~ an hG-CSF protein according to claim 1 and a pharmaceutically acceptable carrier.